NEW YORK – The US Food and Drug Administration today approved tucatinib (Seattle Genetics' Tukysa) in combination with trastuzumab (Genentech's Herceptin) and capecitabine for adults with advanced unresectable or metastatic HER2-positive breast cancer, including those who have experienced brain metastases.